Isi Lapatinib CAS 231277-92-2 Dị Ọcha ≥99.0% (HPLC)

Nkọwa dị mkpirikpi:

Aha kemịkalụ:Lapatinib Base

Ọkụ: 231277-92-2

Dị ọcha: ≥99.5% (HPLC)

Ihe fọrọ nke nta ka ọ bụrụ White ma ọ bụ Light Yellow Crystalline Powder

Kpọtụrụ: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Zitere anyị email

Nkọwa ngwaahịa

Ngwaahịa ndị emetụtara

Mkpado ngwaahịa

Lapatinib Intermediates:

Lapatinib Base	CAS 231277-92-2
Lapatinib Ditosylate Monohydrate	CAS 388082-78-8
Sodium Methanesulfinate	CAS 20277-69-4
3-Chloro-4- (3-Fluorobenzyloxy) aniline	CAS 202197-26-0
2-Aminoethyl Methyl Sulfone Hydrochloride	CAS 104458-24-4
4-Chloro-6-Iodoquinazoline	CAS 98556-31-1
6-Iodo-4-Hydroxyquinazoline	CAS 16064-08-7
5-Formyl-2-Furanboronic acid	CAS 27329-70-0
5-[4-[3-Chloro-4- (3-Fluorobenzyloxy) anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde	CAS 231278-84-5

Njirimara kemịkalụ:

Aha Chemical	Lapatinib Base
Ụdị okwu	Lapatinib;N-[3-Chloro-4-[(3-fluorobenzyl) oxy] phenyl]-6-[5-[[(2- (methylsulfonyl) ethyl] amino] methyl]furan-2-yl] quinazolin-4-amine N-[3-Chloro-4-[(3-fluorobenzyl) oxy] phenyl] -6-[5-[[2- (methylsulfonyl) ethyl] amino] methyl] -2-furyl]-4-quinazolinamine
Nọmba CAS	231277-92-2
Ọnọdụ Ahịa	Dị na ngwaahịa
Usoro ihe omimi	C29H26ClFN4O4S
Ibu molekụla	581.06
Ebe Na-agbaze	141.0 ~ 149.0 ℃
Njupụta	1.381±0.06 g/cm3
COA & MSDS	Dị
Ụdị	Ruifu Chemical

Nkọwapụta:

Ihe	Nkọwapụta
Ọdịdị	Ihe fọrọ nke nta ka ọ bụrụ White ma ọ bụ Light Yellow Crystalline Powder
njirimara	IR;HPLC
Ụzọ ịdị ọcha / nyocha	≥99.0% (HPLC)
Ebe Na-agbaze	141.0 ~ 149.0 ℃
Ọnwụ na ihicha	≤0.50%
Ihe fọdụrụ na mgbanye	≤0.10%
Ọla dị arọ (dị ka Pb)	≤20ppm
Ihe adịghị ọcha nke Organic	Zute ihe achọrọ
Ihe ndị emetụtara
Otu adịghị ọcha	≤0.30%
Mgbakọta adịghị ọcha	≤1.00%
Nlele ọkọlọtọ	Standardkpụrụ ụlọ ọrụ
Ndụ shelf	Afọ 2 mgbe echekwara nke ọma
Ojiji	API, ọgwụgwọ ọnụ maka ọrịa ara ara

Ngwungwu & Nchekwa:

ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ

Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri

Uru:

Ajụjụ:

231277-92-2 - Ngwa:

API (CAS: 231277-92-2)bụ ọgwụgwọ ezubere iche maka ọgwụ ọrịa ara ara, bụ tyrosine kinase inhibitor, nwere ike igbochi onye na-anabata ihe na-eto eto epidermal nke ọma -1 (ErbB1) na onye na-anabata ihe na-eto eto epidermal (ErbB2) tyrosine kinase ọrụ nke -2.Ọ bụ ihe pụrụ iche na ọ nwere ike na-ekere òkè n'ụzọ dịgasị iche iche, nke mere na mkpụrụ ndụ cancer ara enweghị ike ịnweta mgbaàmà dị mkpa maka uto.Usoro nke ime ihe bụ igbochi intracellular EGFR (ErbB-1) na HER2 (ErbB-2) saịtị ATP iji gbochie phosphorylation na ịgbalite mkpụrụ ndụ tumo, na igbochi nkwụsị nke nrịbama site na EGFR (ErbB-1) na HER2 (ErbB-1) jikọtara ọnụ na mkpokọta abụọ.A na-eji ngwakọta nke (CAS: 231277-92-2) na Capecitabine na-agwọ ndị ọrịa nwere ọrịa ara ara dị elu ma ọ bụ metastatic nke na-emebiga ihe ókè nke mmadụ epidermal receptor2, nke ejirila anthracyclines, paclitaxel, na trastuzumab mesoo ya.Nnwale ụlọọgwụ egosila na ọ na-agwọkwa ndị ọrịa cancer ụdị HER2 nke ọma na nguzogide Herceptin.

231277-92-2 - egosi:

Lapatinib jikọtara ya na Capecitabine dabara adaba maka ọgwụgwọ ndị ọrịa kansa ara ma ọ bụ metastatic nwere HER2 (ErbB-2 overexpression) na ọgwụgwọ gara aga gụnyere anthracyclines, paclitaxel na trastuzumab.

231277-92-2 - Mmekọrịta ọgwụ:

Mbadamba ụrọ in vitro Lapatinib nwere ike igbochi CYP3A4 na CYP2C8 na mkpokọta ọgwụgwọ, yana CYP3A4 mebere ya nke ọma.ọgwụ ndị na-egbochi ọrụ enzyme a nwere ike ịbawanye mkpokọta ọgwụ Lapatinib n'ọbara nke ukwuu.Ketoconazole, 0.2g oge ọ bụla, ugboro 2 / d, nwere ike ịbawanye AUC nke Lapatinib site na 3 ~ 7 ugboro ma gbasaa ọkara ndụ site na 1.7 ugboro mgbe ụbọchị 7 gasịrị.Ndị ọrụ afọ ofufo ahụike were ọnụ na-ekwu CYP3A4 inducer, 100 mg oge ọ bụla, ugboro abụọ n'ụbọchị, wee gbanwee na 200mg oge ọ bụla mgbe ụbọchị 3 gachara, na-ekerịta ụbọchị 17 ugboro abụọ n'ụbọchị.AUC nke Lapatinib belatara site na 72%.Lapatinib bụ ebe a na-ebufe P-glycoprotein, yana ọgwụ ndị na-egbochi glycoprotein nwere ike ịbawanye mkpokọta ọbara nke ọgwụ ahụ.

Ọgwụ ọhụrụ maka ọgwụgwọ ezubere iche nke ọrịa ara ara:

Lapatinib bụ ọgwụ ọhụrụ maka ọgwụgwọ ezubere iche maka ọrịa ara ara nke GlaxoSmithKline, UK mepụtara.Ọ bụ onye na-eme ihe na-eme ka tyrosine kinase nke nwere ike igbochi onye na-anabata ihe na-eto eto na-eto eto -1 (ErbB1) na onye na-emepụta ihe na-eto eto nke mmadụ -2 (ErbB2) tyrosine kinase ọrụ.Ọ bụ ihe pụrụ iche na ọ nwere ike ịrụ ọrụ n'ụzọ dị iche iche ka mkpụrụ ndụ kansa ara ghara ịnata akara ndị dị mkpa maka uto.Usoro nke ime ihe bụ igbochi saịtị ATP nke EGFR (ErbB-1) na HER2 (ErbB-2) n'ime sel iji gbochie phosphorylation na ịgbalite mkpụrụ ndụ tumo, na igbochi akara nchịkwa site na homogenous na heterogeneous dimers nke EGFR (ErbB) -1) na HER2 (ErbB-1).Usoro ọgwụgwọ molecular ezubere iche maka ọrịa kansa ara na-ezo aka na ọgwụgwọ oncogenes na ngwaahịa okwu metụtara ya metụtara omume na mmepe nke ọrịa kansa ara.Ọgwụ ndị a na-ezubere iche na-egbochi ma ọ bụ gbuo mkpụrụ ndụ etuto site na igbochi ntụgharị mgbaàmà na mkpụrụ ndụ etuto ma ọ bụ sel ndị metụtara ya iji chịkwaa mgbanwe na mkpụrụ ndụ mkpụrụ ndụ cell.Na Machị 14, 2007, nchịkwa nri na ọgwụ US kwadoro nchikota nke lapatinib na xeloda (capecitabine) maka ọgwụgwọ nke ndị ọrịa ara ara dị elu ma ọ bụ metastatic nke ndị na-anabata ihe na-akpata 2 (ErbB2) na-ebufe ya na anthracyclines, paclitaxel na trastuzumab. .Nnwale ụlọọgwụ na-egosi na ngwaahịa a nwekwara mmetụta ọgwụgwọ dị mma maka ndị na-arịa ọrịa ara ara HER2 bụ ndị mepụtara ọgwụ mgbochi megide Roche's Herceptin (Herceptin).lapatinib bụ ọgwụ ọhụrụ ezubere iche maka mgbochi ọrịa kansa.Ọ nwere ike ime ihe na ebumnuche Her-1 na Her-2 n'otu oge.Mmetụta ndụ nke ụdị omume a na mmụba na uto nke mkpụrụ ndụ tumo dị nnọọ ukwuu karịa nke naanị otu ebumnuche.Ihe a na-akpọ ọgwụ ọgwụgwọ ezubere iche na-ezo aka na ọgwụ ndị na-eji ụfọdụ ndị na-anabata ya, mkpụrụ ndụ ihe nketa ma ọ bụ protein ndị bụ isi dị ka ebumnuche igbu mkpụrụ ndụ tumor ndị metụtara ya n'ụzọ ezubere iche.